版本:
中国

BRIEF-Celgene Corp- releases data on Phase 2 RADIANCE trial

Sept 16 Celgene Corp

* Celgene Corp -Oral Ozanimod efficacy and safety results at 2 years from Phase 2 RADIANCE trial of patients with relapsing multiple Sclerosis presented at 32nd Ectrims

* Celgene Corp -No new safety or tolerability issues were identified during ongoing blinded extension

* Celgene Corp -Radiance met its primary efficacy endpoint _ reduction in cumulative number of total gadolinium-enhancing lesions Source text for Eikon: Further company coverage:

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐